ADASUVE

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Hong Kong SAR China, Ireland, Lithuania, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug ADASUVE contains one active pharmaceutical ingredient (API):

1	Loxapine UNII LER583670J - LOXAPINE
	Loxapine binds with noradrenergic, histaminergic, and cholinergic receptors, and its interaction with these systems may influence the spectrum of its pharmacological effects. Loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.
	Read more about Loxapine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADASUVE Inhalation powder	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AH01	Loxapine	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1608915, 1608926, 1650507, 1650518
ES	Centro de información online de medicamentos de la AEMPS	113823002
GB	Medicines & Healthcare Products Regulatory Agency	326880
HK	Department of Health Drug Office	67228
LT	Valstybinė vaistų kontrolės tarnyba	1069358, 1069359, 1072654, 1072655
PL	Rejestru Produktów Leczniczych	100308516, 100308522
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62549001, W62549002, W62550001, W62550002
TR	İlaç ve Tıbbi Cihaz Kurumu	8699587554079, 8699587554086
US	FDA, National Drug Code	10885-003